ImpediMed moves into the home to help hospitals avoid penalties

A major shift in strategy may often rightly be met with scepticism and concern among shareholders, but ImpediMed chief executive Richard Carreon says applying the medical device maker's technology to heart failure patients is a huge opportunity that the next 12 months should justify.

The Brisbane-based company's L-Dex device looked to be a promising and cost-effective way for hospitals to manage complications in cancer patients. The device aids in the early detection of lymphoedema, a dangerous and painful fluid build-up, especially in the limbs, which is caused by damage to lymph nodes after treatments such as chemotherapy or radiation.